Robert A. Preti, Ph.D.

Dr. Preti is Progenitor Cell Therapy, LLC’s (PCT) co-founder, president, and chief scientific officer. Through his administrative duties, Dr. Preti has overseen the growth of PCT from its inception to its position as a world-leading commercial cell therapy company.

Previous positions held by Dr. Preti include scientific and laboratory director of Hackensack University Medical Center’s stem cell processing and research laboratory in New Jersey and scientific director of the Clinical Services Division at the New York Blood Center, New York City.

He is one of the country’s leading authorities on cell engineering, advanced cell and gene therapy manufacturing, testing and delivery, and regulatory aspects relating to the cell therapy and regenerative medicine industry. He has been the principal investigator for a number of clinical trials relating to the clinical testing of cellular therapies.

Dr. Preti is a founding member the International Society for Cellular Therapies (formerly the International Society for Hematotherapy and Graft Engineering), had served on its executive committee and board of directors for 10 years, and currently serves on the editorial board for the society’s journal, Cytotherapy. He currently serves in his fourth term as director for the AABB an organization whose mission is “Advancing Transfusion and Cellular Therapies Worldwide.” He is a frequently invited speaker at international and national symposia and conferences, addressing a wide range of topics within his expertise in the clinical development programs for cellular therapies, including the business, financial, logistic, manufacturing, product development, testing, quality, and regulatory aspects of successful commercialization.

Dr. Preti received his doctor of philosophy degree from New York University, graduating with distinction.

Comments are closed.